Sopharma AD - Asset Resilience Ratio
Sopharma AD (SPH) has an Asset Resilience Ratio of 0.00% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore long-term investment intensity of Sopharma AD to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how Sopharma AD's Asset Resilience Ratio has changed over time. See SPH days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Sopharma AD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sopharma AD (SPH) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł80.00K | 0.0% |
| Total Liquid Assets | zł80.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sopharma AD maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sopharma AD Industry Peers by Asset Resilience Ratio
Compare Sopharma AD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC |
Medical Distribution | 5.70% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.21% |
Annual Asset Resilience Ratio for Sopharma AD (2013–2023)
The table below shows the annual Asset Resilience Ratio data for Sopharma AD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.02% | zł-271.00K ≈ $-74.58K |
zł1.51 Billion ≈ $416.72 Million |
-0.01pp |
| 2022-12-31 | -0.01% | zł-140.00K ≈ $-38.53K |
zł1.26 Billion ≈ $345.61 Million |
-0.05pp |
| 2016-12-31 | 0.04% | zł316.00K ≈ $86.97K |
zł859.22 Million ≈ $236.47 Million |
0.00pp |
| 2015-12-31 | 0.04% | zł314.00K ≈ $86.42K |
zł835.63 Million ≈ $229.98 Million |
+0.12pp |
| 2013-12-31 | -0.08% | zł-638.00K ≈ $-175.59K |
zł782.79 Million ≈ $215.43 Million |
-- |
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more